GlassScriptPhysician profile
Diana Carmona
NPI 1841262656
$915.66
in general payments reported to CMS, 2019-2025
20 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.59 · 2021: $27.12 · 2023: $46.63 · 2024: $333 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $189.54 | 2024-2025 | Nexplanon, Jada System |
| Sage Therapeutics, LLC | $124.72 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $111.62 | 2023-2025 | |
| Amgen INC. | $65.29 | 2025 | Evenity |
| Abbvie INC. | $63.26 | 2023-2024 | Liletta |
| Mayne Pharma Commercial LLC | $58.31 | 2025 | |
| Sumitomo Pharma America, INC. | $44.05 | 2024 | Gemtesa |
| Millicent US INC | $33.78 | 2025 | Femlyv, Intrarosa |
| Merck Sharp & Dohme LLC | $33.31 | 2019-2025 | Gardasil 9 |
| Astellas Pharma US INC | $31.14 | 2024-2025 | Veozah |
| Novo Nordisk INC | $27.92 | 2024-2025 | Wegovy |
| Axonics, INC. | $20.41 | 2024 | Bulkamid, Axonics |
| Ethicon US, LLC | $19.82 | 2025 | Vicryl |
| Pfizer INC. | $17.44 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.68 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $14.42 | 2024 | Fibryga |
| Exeltis, USA INC. | $14.33 | 2024 | Slynd |
| Minerva Surgical, INC | $11.77 | 2019 | |
| Alydia Health | $9.68 | 2021 | |
| Meditrina | $9.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Carmona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.